{"commentary":{"count":113,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":81,"youtube":22,"podcast":10},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03137771\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03137771","nct_id":"NCT03137771","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03137771. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride by mouth daily, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Arm 1 (systemic maintenance chemotherapy)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo local consolidative therapy (LCT) over 2-5 weeks, consisting of SBRT/hypofractionated radiation to the primary tumor and metastatic sites or surgery of metastatic sites. Hypofractionated radiation using IMRT or 3D-CRT can be given in place of SBRT. Within 2 weeks after completion of LCT (3 weeks if surgery occurred), patients receive chemotherapy as in Arm 1.","label":"Arm 2 (LCT + systemic maintenance chemotherapy)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer"],"enrollment":{"count":218,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"3-Dimensional Conformal Radiation Therapy (3D-CRT)","type":"RADIATION"},{"name":"Docetaxel","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Intensity-Modulated Radiation Therapy (IMRT)","type":"RADIATION"},{"name":"Pemetrexed Disodium","type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy (SBRT)","type":"RADIATION"},{"name":"Erlotinib Hydrochloride","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2026-06-08","lead_sponsor":"NRG Oncology","official_title":"Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-12-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"[Phase II] Progression-free Survival","timeFrame":"From randomization to first date of local or regional disease, distant metastases, second primary tumor, death, or last follow-up, whichever comes first. Maximum follow-up time at time of analysis was 5.4 years."},{"measure":"[Phase III] Overall Survival","timeFrame":"From randomization to death or last follow-up."}],"references":[{"citation":"Mattes MD, Eubank TD, Almubarak M, Wen S, Marano GD, Jacobson GM, Ma PC. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021 Jul;22(4):268-273. doi: 10.1016/j.cllc.2021.01.012. Epub 2021 Jan 25.","pmid":"33608212","type":"DERIVED"}],"start_date":{"date":"2017-04-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03137771"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03137771"}